Tiba

Tiba Biotech is a preclinical-stage biopharmaceutical company focused on developing a next-generation mRNA vaccine and therapeutic platform. The company's proprietary RNABoost technology utilizes a unique dendrimer-based nanoparticle delivery system designed to improve the stability, safety, and manufacturing scalability of mRNA treatments compared to traditional lipid nanoparticles. Tiba's current pipeline targets a broad range of infectious diseases, including COVID-19, influenza, and dengue, while also exploring applications in oncology and animal health. Through strategic partnerships with organizations like CEPI, the company aims to provide rapidly deployable and accessible medical countermeasures for global health threats.